Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation (ORLY-Est)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02843867 |
|
Recruitment Status :
Recruiting
First Posted : July 26, 2016
Last Update Posted : July 26, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The incidence of atherosclerotic complications is increased after kidney transplantation. Traditional risk factors do not fully explain this increased risk. Atherosclerosis is an inflammatory disease in which all players in the immune response are involved. The impact of these immune responses is not well known in immunocompromised patients, particularly among organ transplant. Nevertheless, the work of our group suggest that innate and acquired responses through different mechanisms influencing the evolution of atheromatous disease after transplantation.
The investigators therefore propose to study the impact of the expansion of regulatory T cells on the risk of atherosclerotic complications after transplantation.
Since November 2008, the investigators began a multicenter, prospective study whose purpose is to study in detail the immunological mechanisms of atherosclerosis after transplantation via immunomonitoring cohort of renal transplant patients in the Grand East Interregion. It was planned to include 500 patients and to date a little more than half have been included. After completion of the blood test, the tubes are routed over the Biomonitoring Platform (CIC-BT 506 Besançon) and the samples are stored in CRB Dijon.
The atherosclerotic events are recorded prospectively. The investigators hope to implement as part of ORLY IS, a second study to determine the impact of an expansion of regulatory T cells on the risk of atherosclerotic events.
Our hypothesis is that a cell rate regulatory T below the median results in an increase of 5% of atherosclerotic complications.
| Condition or disease | Intervention/treatment |
|---|---|
| Disorder Related to Renal Transplantation | Other: blood sample |
| Study Type : | Observational |
| Estimated Enrollment : | 1000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Influence de l'ORientation de la réponse LYmphocytaire Sur la Survenue de Complications athéromateuses après Transplantation rénale (étude ORLY-EST 2) |
| Study Start Date : | November 2008 |
| Estimated Primary Completion Date : | September 2017 |
| Estimated Study Completion Date : | September 2026 |
- Other: blood sample
36 ml of blood sample at D0 and 1 year after transplantation
- Percentage of regulatory T cells related to atherosclerotic complications events. [ Time Frame: 5 or 10 years ]
- Atherosclerotic complications events [ Time Frame: 5 or 10 years ]
- Genetic determinants (TNF-alpha, IL-6,...) related to cardiovascular events [ Time Frame: 5 or 10 years ]
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Male or female patients aged over 18 years
- Patients receiving a renal transplant
- Patients able to understand the benefits and risks of testing
- Patients gave written informed consent.
Exclusion Criteria:
- Inability to understand the advantages and disadvantages of the study; psychiatric disorders judged by the investigator to be incompatible with the inclusion in the study.
- Immunosuppressive therapy immediately prior to transplantation
- Cancer (except skin cancer) or malignant blood disease being treated; active infection; decompensated cirrhosis [patients had cancer and considered as cured or in remission, patients with virus infection of hepatitis B or hepatitis C and having no cirrhosis may be included].
This study is strictly non-interventional, participation in another study is not a cons-indication to the inclusion in this study and no exclusion period is required for inclusion in another study after inclusion in this study (Art L. 1121-12 (loi n°2004-806 du 9 Août 2004).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02843867
| Contact: Didier Ducloux, Pr. | dducloux@chu-besancon.fr | ||
| Contact: Emilie Gaiffe, Dr. | egaiffe@chu-besancon.fr |
| France | |
| CHU de Besançon | Recruiting |
| Besançon, France, 25000 | |
| Contact: Didier Ducloux, Pr. | |
| CHU Clermont-Ferrand, 58 rue Montalembert, 63003 Clermont-Ferrand | Recruiting |
| Clermont-Ferrand, France, 63003 | |
| Contact: Patrick Detex, Pr. | |
| CHU Dijon, Hôpital du Bocage, 2 Bd du Maréchal de Lattre de Tassigny, 21079 Dijon cedex | Recruiting |
| Dijon, France, 21079 | |
| Contact: Christiane Mousson, Pr. | |
| Hôpital du Kremlin Bicêtre 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex | Recruiting |
| Le Kremlin-Bicêtre, France, 94275 | |
| Contact: Antoine Durrbach, Pr. | |
| CHU Brabois, et Vandoeuvre les Nancy | Active, not recruiting |
| Nancy, France | |
| CHU Reims, 45 rue Cognacq-Jay 51092 Reims Cedex | Active, not recruiting |
| Reims, France, 51092 | |
| Hôpital Civil- 1, place de l'hôpital BP426 ; 67091 Strasbourg Cedex | Active, not recruiting |
| Strasbourg, France, 67091 | |
| Principal Investigator: | Didier Ducloux, Pr. | CHRU de Besançon |
| Responsible Party: | Centre Hospitalier Universitaire de Besancon |
| ClinicalTrials.gov Identifier: | NCT02843867 |
| Other Study ID Numbers: |
R/2011/44 |
| First Posted: | July 26, 2016 Key Record Dates |
| Last Update Posted: | July 26, 2016 |
| Last Verified: | July 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Identified individual participant data for all outcome measures will be made available within 6 monts of study completion |
|
Transplantation Immunology Atherosclerosis |